Thus, the APOL1 pore function inhibitor can potentially complement the effects of these drugs in the treatment of kidney disease patients, especially among Africans with a high burden of kidney disease and where the frequency of APOL1 high-risk alleles is high. Here, APOL1 is linked to kidney disorder.